Pfizer and the German biotechnology company BioNTech can neutralise variants of the novel coronavirus that were first reported in the UK and South Africa, a new study suggests.The research, published in the journal Nature Medicine, noted that the vaccine is effective against coronavirus variants carrying the N501Y and E484K mutations.Also Read | India should worry about its public debtAccording to the scientists, including those from the University of Texas in the US, these variants have a substitution of the amino acid building blocks that make up the viral spike protein -- the part of the virus which enables it to enter human cells.They said these mutations in the 501st and 484th positions of the protein's amino acid molecule chain.
Read more on livemint.com